Leap Therapeutics Inc (OQ:LPTX)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 47 Thorndike St Ste B1-1
CAMBRIDGE MA 02141-1799
Tel: N/A
Website: https://www.leaptx.com
IR: See website
<
Key People
N/A    
Business Overview
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Financial Overview
For the six months ended 30 June 2019, Leap Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 4% to $17.3M. Lower net loss reflects Change in fair value of warrant liabilit decrease from $5.5M (expense) to $0K, General and Administrative - Balancing decrease of 16% to $2.8M (expense), Foreign currency losses decrease of 91% to $34K (expense).
Employees: 23 as of Mar 26, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $20.07M as of Jun 30, 2019
Annual revenue (TTM): $0.00M as of Jun 30, 2019
EBITDA (TTM): -$34.78M as of Jun 30, 2019
Net annual income (TTM): -$22.48M as of Jun 30, 2019
Free cash flow (TTM): -$28.55M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 24,038,799 as of Aug 6, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization